A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein-Reference-Cited by-同舟云学术

A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein

Published:2022-04 Issue:15 Volume:40 Page:2299-2310
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Huang Hong-Jyun^ORCID,Yang Martyr,Chen Hsin-Wei,Wang Shuying,Chang Chih-Peng^ORCID,Ho Tzong-Shiann^ORCID,Kao Yu-San^ORCID,Tien Sen-Mao,Lin Hsing-Han,Chang Po-Chun,Lai Yen-Chung^ORCID,Hsiao Yu-Peng,Liu Yi-Ling,Chao Chiao-Hsuan,Anderson Robert,Yeh Trai-Ming,Lin Yee-Shin,Wan Shu-Wen^ORCID

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference59 articles.

1. Dengue

2. The global distribution and burden of dengue;Bhatt;Nature,2013

3. Molecular insight into dengue virus pathogenesis and its implications for disease control;Diamond;Cell,2015

4. Dengue: knowledge gaps, unmet needs, and research priorities;Katzelnick;Lancet Infect Dis.,2017

5. Identifying protective dengue vaccines: guide to mastering an empirical process;Halstead;Vaccine.,2013

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying Key Drivers of Efficient B Cell Responses: On the Role of T Help, Antigen-Organization, and Toll-like Receptor Stimulation for Generating a Neutralizing Anti-Dengue Virus Response;Vaccines;2024-06-14

2. Dominant epitopes of cross‐reactive anti‐domain III human antibody response change from early to late convalescence of infection with dengue virus;Journal of Medical Virology;2024-02

3. A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells;Vaccine;2023-02